Nmo Spectrum Disorder

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2020-12-31
Clinical Trial Update: Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD) [Phase 3]
Phase 3 trial evaluating satralizumab as add-on therapy for neuromyelitis optica and NMOSD completed with posted results.